Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N06AX21

Duloxetine Lilly(duloxetine)

Neuralgia;Diabetic Neuropathies;Depressive Disorder, Major

Marketing Authorisation Holder: Eli Lilly Nederland B.V.

EMA Authorisation: 08/12/2014

INN: duloxetine

Indication

Duloxetine Lilly is indicated in adults for: Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Lilly is indicated in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Duloxetine Lilly — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.